Which has higher valuation and earnings, SRRK or TYRA?

Scholar Rock is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is SRRK or TYRA more profitable?

Tyra Biosciences' return on equity of -46.39% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Tyra Biosciences N/A -46.39% -43.07%

Does the media refer more to SRRK or TYRA?

In the previous week, Tyra Biosciences had 16 more articles in the media than Scholar Rock. MarketBeat recorded 28 mentions for Tyra Biosciences and 12 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.62 beat Tyra Biosciences' score of 0.10 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CGON or TYRA?

In the previous week, Tyra Biosciences had 23 more articles in the media than CG Oncology. MarketBeat recorded 28 mentions for Tyra Biosciences and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.22 beat Tyra Biosciences' score of 0.10 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to MIRM or TYRA?

In the previous week, Tyra Biosciences had 24 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 28 mentions for Tyra Biosciences and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.25 beat Tyra Biosciences' score of 0.10 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor TVTX or TYRA?

In the previous week, Tyra Biosciences had 19 more articles in the media than Travere Therapeutics. MarketBeat recorded 28 mentions for Tyra Biosciences and 9 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.20 beat Tyra Biosciences' score of 0.10 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ORKA or TYRA?

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oruka Therapeutics N/A N/A -$105.43M -$2.03 N/A Tyra Biosciences N/A N/A -$119.95M -$2.40 N/A

Is ORKA or TYRA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Tyra Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oruka Therapeutics N/A -21.65% -20.88% Tyra Biosciences N/A -46.39% -43.07%

Does the media favor ORKA or TYRA?

In the previous week, Tyra Biosciences had 20 more articles in the media than Oruka Therapeutics. MarketBeat recorded 28 mentions for Tyra Biosciences and 8 mentions for Oruka Therapeutics. Tyra Biosciences' average media sentiment score of 0.10 beat Oruka Therapeutics' score of -0.07 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tyra Biosciences 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral

Tyra Biosciences (TYRA) Competitors

$22.03 -1.51 (-6.41%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$22.22 +0.20 (+0.89%)

As of 09/11/2026 07:55 PM Eastern

Compare

TYRA vs. SRRK, CGON, MIRM, TVTX, and ORKA

Should you buy Tyra Biosciences stock or one of its competitors? Tyra Biosciences's main competitors and comparable companies include Scholar Rock (SRRK), CG Oncology (CGON), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and Oruka Therapeutics (ORKA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tyra Biosciences compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Scholar Rock presently has a consensus price target of $58.77, suggesting a potential upside of 6.06%. Tyra Biosciences has a consensus price target of $47.88, suggesting a potential upside of 117.32%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	3.06
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Tyra Biosciences' return on equity of -46.39% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Tyra Biosciences	N/A	-46.39%	-43.07%

Scholar Rock is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

In the previous week, Tyra Biosciences had 16 more articles in the media than Scholar Rock. MarketBeat recorded 28 mentions for Tyra Biosciences and 12 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.62 beat Tyra Biosciences' score of 0.10 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

Summary

Tyra Biosciences beats Scholar Rock on 10 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CG Oncology has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Tyra Biosciences has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -25.20% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Tyra Biosciences	N/A	-46.39%	-43.07%

In the previous week, Tyra Biosciences had 23 more articles in the media than CG Oncology. MarketBeat recorded 28 mentions for Tyra Biosciences and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.22 beat Tyra Biosciences' score of 0.10 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology presently has a consensus target price of $87.78, suggesting a potential upside of 21.32%. Tyra Biosciences has a consensus target price of $47.88, suggesting a potential upside of 117.32%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Tyra Biosciences has lower revenue, but higher earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,587.40	-$160.99M	-$2.69	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Summary

Tyra Biosciences beats CG Oncology on 11 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Tyra Biosciences had 24 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 28 mentions for Tyra Biosciences and 4 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.25 beat Tyra Biosciences' score of 0.10 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mirum Pharmaceuticals has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

84.1% of Tyra Biosciences shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mirum Pharmaceuticals currently has a consensus price target of $137.31, suggesting a potential upside of 39.80%. Tyra Biosciences has a consensus price target of $47.88, suggesting a potential upside of 117.32%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Tyra Biosciences has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%
Tyra Biosciences	N/A	-46.39%	-43.07%

Mirum Pharmaceuticals has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	12.23	-$23.36M	-$14.55	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Summary

Mirum Pharmaceuticals beats Tyra Biosciences on 9 of the 16 factors compared between the two stocks.

How does Tyra Biosciences compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

84.1% of Tyra Biosciences shares are owned by institutional investors. 4.4% of Travere Therapeutics shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Travere Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Travere Therapeutics presently has a consensus price target of $68.00, indicating a potential upside of 2.77%. Tyra Biosciences has a consensus price target of $47.88, indicating a potential upside of 117.32%. Given Tyra Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Travere Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Tyra Biosciences had 19 more articles in the media than Travere Therapeutics. MarketBeat recorded 28 mentions for Tyra Biosciences and 9 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.20 beat Tyra Biosciences' score of 0.10 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

Travere Therapeutics has higher revenue and earnings than Tyra Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Travere Therapeutics	$490.73M	12.71	-$25.55M	-$0.46	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Tyra Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Tyra Biosciences' return on equity of -46.39% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Travere Therapeutics	-7.35%	-55.15%	-6.88%
Tyra Biosciences	N/A	-46.39%	-43.07%

Summary

Tyra Biosciences beats Travere Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Oruka Therapeutics presently has a consensus price target of $133.00, indicating a potential upside of 43.97%. Tyra Biosciences has a consensus price target of $47.88, indicating a potential upside of 117.32%. Given Tyra Biosciences' higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Tyra Biosciences had 20 more articles in the media than Oruka Therapeutics. MarketBeat recorded 28 mentions for Tyra Biosciences and 8 mentions for Oruka Therapeutics. Tyra Biosciences' average media sentiment score of 0.10 beat Oruka Therapeutics' score of -0.07 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tyra Biosciences	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	8 Negative mention(s)	1 Very Negative mention(s)	Neutral

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Oruka Therapeutics has a beta of -0.34, suggesting that its stock price is 134% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market.

Oruka Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Oruka Therapeutics' return on equity of -21.65% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-21.65%	-20.88%
Tyra Biosciences	N/A	-46.39%	-43.07%

Summary

Tyra Biosciences beats Oruka Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TYRA vs. The Competition

Export

Metric	Tyra Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.31B	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-9.18	14.18	274.94	25.33
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	4.53	15.12	10.33	6.21
Net Income	-$119.95M	-$22.86M	$3.50B	$358.54M
7 Day Performance	-23.11%	-4.34%	-3.32%	-2.35%
1 Month Performance	-11.95%	0.54%	-0.53%	-3.23%
1 Year Performance	75.96%	40.74%	23.51%	8.79%

Tyra Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TYRA Tyra Biosciences	3.1393 of 5 stars	$22.03 -6.4%	$47.88 +117.3%	+76.0%	$1.31B	N/A	N/A	87	Trending News Analyst Forecast Gap Down
SRRK Scholar Rock	1.7962 of 5 stars	$57.42 +3.8%	$58.77 +2.3%	+75.0%	$6.74B	N/A	N/A	140	News Coverage Analyst Forecast
CGON CG Oncology	3.1426 of 5 stars	$73.40 -1.7%	$87.78 +19.6%	+117.0%	$6.62B	$4.04M	N/A	61	Positive News Options Volume
MIRM Mirum Pharmaceuticals	2.7498 of 5 stars	$99.53 -1.4%	$137.31 +38.0%	+32.2%	$6.55B	$521.31M	N/A	140	Gap Down
TVTX Travere Therapeutics	1.6744 of 5 stars	$66.07 +1.2%	$61.67 -6.7%	+181.9%	$6.15B	$490.73M	N/A	460	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TYRA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tyra Biosciences (TYRA) Competitors

TYRA vs. SRRK, CGON, MIRM, TVTX, and ORKA

How does Tyra Biosciences compare to Scholar Rock?

Summary

How does Tyra Biosciences compare to CG Oncology?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Summary

How does Tyra Biosciences compare to Travere Therapeutics?

Summary

How does Tyra Biosciences compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tyra Biosciences (TYRA) Competitors

TYRA vs. SRRK, CGON, MIRM, TVTX, and ORKA

How does Tyra Biosciences compare to Scholar Rock?

Do insiders and institutionals hold more shares of SRRK or TYRA?

Do analysts prefer SRRK or TYRA?

Is SRRK or TYRA more profitable?

Which has higher valuation and earnings, SRRK or TYRA?

Does the media refer more to SRRK or TYRA?

Which has more volatility & risk, SRRK or TYRA?

Summary

How does Tyra Biosciences compare to CG Oncology?

Do institutionals and insiders have more ownership in CGON or TYRA?

Which has more risk and volatility, CGON or TYRA?

Is CGON or TYRA more profitable?

Does the media refer more to CGON or TYRA?

Do analysts rate CGON or TYRA?

Which has better valuation and earnings, CGON or TYRA?

Summary

How does Tyra Biosciences compare to Mirum Pharmaceuticals?

Does the media refer more to MIRM or TYRA?

Which has more volatility and risk, MIRM or TYRA?

Do insiders & institutionals hold more shares of MIRM or TYRA?

Do analysts rate MIRM or TYRA?

Is MIRM or TYRA more profitable?

Which has higher valuation and earnings, MIRM or TYRA?

Summary

How does Tyra Biosciences compare to Travere Therapeutics?

Do insiders & institutionals have more ownership in TVTX or TYRA?

Which has more risk and volatility, TVTX or TYRA?

Do analysts rate TVTX or TYRA?

Does the media favor TVTX or TYRA?

Which has preferable earnings & valuation, TVTX or TYRA?

Is TVTX or TYRA more profitable?

Summary

How does Tyra Biosciences compare to Oruka Therapeutics?

Do analysts prefer ORKA or TYRA?

Does the media favor ORKA or TYRA?

Do institutionals & insiders have more ownership in ORKA or TYRA?

Which has more volatility and risk, ORKA or TYRA?

Which has stronger earnings & valuation, ORKA or TYRA?

Is ORKA or TYRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA vs. The Competition

Tyra Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools